Chromadex Corp (NASDAQ:CDXC) Expected to Announce Earnings of -$0.13 Per Share

Share on StockTwits

Wall Street brokerages expect Chromadex Corp (NASDAQ:CDXC) to announce ($0.13) earnings per share (EPS) for the current quarter, according to Zacks. Two analysts have made estimates for Chromadex’s earnings. Chromadex posted earnings per share of ($0.15) during the same quarter last year, which indicates a positive year-over-year growth rate of 13.3%. The company is expected to report its next quarterly earnings results on Thursday, August 8th.

According to Zacks, analysts expect that Chromadex will report full year earnings of ($0.46) per share for the current financial year, with EPS estimates ranging from ($0.47) to ($0.45). For the next financial year, analysts expect that the business will report earnings of ($0.05) per share, with EPS estimates ranging from ($0.14) to $0.09. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that follow Chromadex.

Chromadex (NASDAQ:CDXC) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($0.15) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.11) by ($0.04). The firm had revenue of $10.05 million during the quarter, compared to analyst estimates of $9.80 million. Chromadex had a negative return on equity of 108.84% and a negative net margin of 94.78%.

A number of analysts recently commented on the company. BidaskClub lowered Zebra Technologies from a “hold” rating to a “sell” rating in a research report on Friday, May 24th. Zacks Investment Research lowered Haynes International from a “hold” rating to a “sell” rating in a research report on Wednesday, May 8th. ValuEngine lowered Wave Life Sciences from a “strong-buy” rating to a “buy” rating in a research report on Monday, March 25th. Finally, HC Wainwright set a $55.00 price objective on Acer Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, May 28th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $6.00.

Several institutional investors have recently bought and sold shares of the company. Resources Investment Advisors Inc. grew its position in shares of Chromadex by 125.0% during the 4th quarter. Resources Investment Advisors Inc. now owns 9,000 shares of the company’s stock worth $31,000 after buying an additional 5,000 shares during the period. Northern Trust Corp grew its position in shares of Chromadex by 1.2% during the 4th quarter. Northern Trust Corp now owns 411,436 shares of the company’s stock worth $1,412,000 after buying an additional 5,009 shares during the period. BNP Paribas Arbitrage SA acquired a new position in shares of Chromadex during the 1st quarter worth about $34,000. Woodard & Co. Asset Management Group Inc. ADV bought a new position in shares of Chromadex during the 1st quarter valued at about $42,000. Finally, Rhumbline Advisers lifted its holdings in shares of Chromadex by 53.3% during the 4th quarter. Rhumbline Advisers now owns 48,511 shares of the company’s stock valued at $166,000 after purchasing an additional 16,863 shares in the last quarter. Institutional investors own 18.11% of the company’s stock.

CDXC stock traded up $0.27 during midday trading on Thursday, reaching $4.77. The stock had a trading volume of 15,775 shares, compared to its average volume of 315,925. The business’s fifty day moving average price is $4.19. The company has a current ratio of 2.24, a quick ratio of 1.68 and a debt-to-equity ratio of 0.07. The company has a market capitalization of $241.52 million, a price-to-earnings ratio of -7.68 and a beta of 1.26. Chromadex has a twelve month low of $2.79 and a twelve month high of $5.00.

Chromadex Company Profile

ChromaDex Corporation operates as a nutraceutical company. The company offers Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide (NAD) level used for healthy aging; and Immulina, a spirulina extract and compound, which is used for improving human immune function.

Featured Story: Trading Strategy

Get a free copy of the Zacks research report on Chromadex (CDXC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Chromadex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromadex and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

1,362 Shares in Hamilton Lane Inc  Acquired by Zurcher Kantonalbank Zurich Cantonalbank
1,362 Shares in Hamilton Lane Inc Acquired by Zurcher Kantonalbank Zurich Cantonalbank
ANGI Homeservices Inc  Holdings Boosted by Zurcher Kantonalbank Zurich Cantonalbank
ANGI Homeservices Inc Holdings Boosted by Zurcher Kantonalbank Zurich Cantonalbank
Athabasca Oil  Share Price Passes Above Two Hundred Day Moving Average of $0.84
Athabasca Oil Share Price Passes Above Two Hundred Day Moving Average of $0.84
ProShares UltraPro Short Dow30  Share Price Cross Above 200-Day Moving Average of $30.44
ProShares UltraPro Short Dow30 Share Price Cross Above 200-Day Moving Average of $30.44
Brokerages Expect Diana Shipping Inc  Will Post Earnings of $0.03 Per Share
Brokerages Expect Diana Shipping Inc Will Post Earnings of $0.03 Per Share
China Fund  Stock Price Crosses Above 200-Day Moving Average of $19.91
China Fund Stock Price Crosses Above 200-Day Moving Average of $19.91


 
© 2006-2019 Zolmax.